secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009886
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable
--------------------------------------------------------------------------

- Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.
- 1,250 patient start forms since launch (207 in Q4), ~12.5% of U.S. PWS addressable market.
- 630 unique prescribers, 136 new in Q4; discontinuation rate ~12% for adverse events.
- Achieved profitability and positive cash flow; year-end cash ~$500M after $100M buyback.
- Company responded to EMA Day 120 questions; ~60% of total lives covered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526009886/0001193125-26-009886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526009886/d18767d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer